Blood Bank Quality Assurance

Several authorities may evaluate the same blood bank. Federal regulations set legal requirements. Accreditation standards apply when a facility holds that accreditation or has adopted the standard. The laboratory must identify every requirement that applies to its activities and build procedures that satisfy them together.

FDA identifies transfusion services among establishments that must report a qualifying deviation involving a distributed product, and federal records rules require traceability through compatibility testing, storage, distribution, and final disposition.^{3,43 US Food and Drug Administration. Biological product deviations. 2026.4 Electronic Code of Federal Regulations. 21 CFR §606.160. 2026.}

The current AABB edition is the 35th edition, effective April 1, 2026.^{11 Association for the Advancement of Blood &… Standards for Blood Banks and Transfusion Services. 2026.}

CAP updates its checklists annually and customizes each inspection checklist to the laboratory's testing menu. Its public checklist catalog assigns general quality management, proficiency testing, procedures, reporting, reagents, equipment, and method verification to All Common. The Transfusion Medicine checklist adds immunohematology, compatibility testing, component storage and modification, transfusion procedures, and adverse reactions.^{5,65 College of American Pathologists. Accreditation checklists. 2026.6 College of American Pathologists. CAP Accreditation Checklists. 2025.}

Three related terms describe different levels of control:

The AABB framework addresses organization, resources, equipment, suppliers and customers, process control, documents and records, deviations and adverse events, assessments, process improvement, and facilities and safety. Evidence from each area supports assessment of the others.^{11 Association for the Advancement of Blood &… Standards for Blood Banks and Transfusion Services. 2026.}

The general quality management lesson explains statistical control, method evaluation, proficiency-testing rules, and quality management across laboratory disciplines.

Each critical step requires an approved procedure, assigned responsibility, acceptance criteria, a record, and a defined response to failure. Each control detects specific failures. An instrument self-check assesses equipment performance. Reagent and specimen controls assess other parts of the testing process.

Current CMS immunohematology guidance directs laboratories to the manufacturer's recommendations for quality control of antibody-identification panels, which generally have no separate daily requirement. A laboratory using multiple racks of reagent typing sera and cells should test a representative sample of each reagent lot in use on each day of testing and each new lot when first used. The laboratory must document every control procedure it performs.^{22 Centers for Medicare & Medicaid Services. State Operations Manual, Appendix C. 2026.}

A negative conventional tube antiglobulin test is valid only when the required IgG-sensitized control cells (cells coated with known IgG, whose agglutination proves the antiglobulin reagent is active) react after addition. Column and solid-phase systems use their own manufacturer-specified controls. The special serologic methods lesson covers these method controls in detail.

Storage monitoring combines fixed requirements with facility-defined intervals. CLIA requires an audible alarm to monitor proper blood and component storage temperature over a 24-hour period and requires documented alarm inspections. Under the current AABB edition, electronic storage devices for blood and components are monitored continuously, and the temperature is recorded at least every 4 hours. AABB also requires quality-control testing of automated temperature-recording devices and alarm activation at facility-defined intervals.^{2,72 Centers for Medicare & Medicaid Services. State Operations Manual, Appendix C. 2026.7 Association for the Advancement of Blood &… Significant Changes and Response to Comments Received to the… 2026.}

A new analyzer, interface, or label can introduce failures that the previous process did not have. Validation detects these failures before the process is used for patients. Validation establishes recorded evidence that a process will consistently meet predetermined specifications under its intended conditions. Verification confirms that a defined requirement has been met. Equipment qualification demonstrates installation, operation, and performance for the intended use. The evidence needed depends on the change and its risk.^{1,21 Association for the Advancement of Blood &… Standards for Blood Banks and Transfusion Services. 2026.2 Centers for Medicare & Medicaid Services. State Operations Manual, Appendix C. 2026.}

Before a new or changed process supports patient testing or component release, the laboratory:

1. Defines the intended use, workflow boundaries, responsible roles, and hazards.
2. Sets acceptance criteria before collecting validation data.
3. Challenges the complete process under expected and adverse conditions, including weak, discrepant, incompatible, invalid, and downtime cases that the process is intended to handle.
4. Tests calculations, decision rules, data transfer, labels, audit trails, and manual fallback when an information system is involved.
5. Resolves failures, approves the evidence, issues controlled procedures, and trains personnel.
6. Confirms competency before independent work and monitors performance after implementation.

A new reagent lot requires acceptance under the existing validated method. The package insert and controlled procedure define the scope of the comparison. A new analyzer, serologic platform, electronic-crossmatch algorithm, interface, component label, temporary storage container, or major workflow change needs evidence that covers the full affected process. CAP's All Common checklist and AABB's process-control standards place validation and verification within the laboratory's active quality system.^{1,5,61 Association for the Advancement of Blood &… Standards for Blood Banks and Transfusion Services. 2026.5 College of American Pathologists. Accreditation checklists. 2026.6 College of American Pathologists. CAP Accreditation Checklists. 2025.}

An interface that turns an invalid screen into a negative result

A transfusion service is replacing the interface that transmits analyzer results to its laboratory information system (LIS). The intended use covers patient and specimen matching, ABO and D results, antibody-screen results and flags, technologist review, and the information passed to compatibility testing and reports. The blood-bank supervisor is responsible for the test plan, an information technology analyst maintains the interface configuration, bench scientists execute challenges, and the medical director approves clinical use. Hazards include attaching results to the wrong patient, losing a warning, treating an unfinished test as negative, and duplicating results after downtime.

FDA's guidance for blood-establishment computer systems recommends testing interfaces in their actual intended workflows, using a risk assessment to determine the extent of testing. The criteria and observations below are one laboratory's local choices. Each laboratory sets its own sample counts and acceptable error rates from its risk assessment.^{88 US Food and Drug Administration. Blood Establishment Computer System Validation in the User's… 2013.}

Before testing, the team approves these acceptance criteria: identifiers and result meanings agree at each destination; weak and discrepant results retain their flags and need review before release; invalid and unfinished results cannot be released as completed results; corrections retain the original result and identify the reviewer and time; and interrupted messages can be reconciled without loss or duplicate active results. Unresolved antibody-screen results are ineligible for electronic crossmatch under this laboratory's established rules. If any safety criterion fails, the change is not released for clinical use.

Testing uses test patient records in a separate test environment with the planned configuration. For each challenge, the scientist records the input, expected result, actual result, pass or fail, operator, and date, with linked screen and report evidence.^{88 US Food and Drug Administration. Blood Establishment Computer System Validation in the User's… 2013.}

The invalid-result challenge fails. Routine cases pass, but an analyzer message containing an invalid antibody-screen flag and an empty interpretation field becomes "negative" in the LIS. The electronic-crossmatch eligibility check then accepts the screen as complete. The scientist records the failure and the team postpones go-live. The other planned challenges meet their expected results. No patient records are involved.

The analyst compares the original message, interface log, and receiving record. A default mapping converts an empty field to "negative" before checking result status. The corrected mapping requires an explicit valid final result code and preserves invalid or unknown states for review. The team records the configuration version, cause, correction, and functions that share this mapping.

The scientist repeats the failed challenge. The LIS now displays "unresolved," retains the analyzer flag, and removes electronic-crossmatch eligibility. Because the mapping is shared, the team also rechecks blank and unknown codes, weak positives, ABO discrepancies, corrections, report displays, and recovery after interruption, alongside previously successful routine cases. Each now meets its recorded expected result. Related functions are rechecked because a correction can introduce a failure outside the challenge that first detected the error.^{88 US Food and Drug Administration. Blood Establishment Computer System Validation in the User's… 2013.}

Approval and implementation. The supervisor reviews the complete test record, including the original failure and its resolution. The medical director signs the release approval only after the criteria are met. Controlled procedures identify the approved configuration, review holds, downtime reconciliation, and return to the prior process if a safety failure appears. Staff practice invalid results and downtime recovery and demonstrate those tasks before independent use. The approved configuration is transferred under change control. The supervisor assigns daily review of interface errors and result reconciliation during the locally chosen introductory monitoring period, with a documented review before reducing that frequency.^{88 US Food and Drug Administration. Blood Establishment Computer System Validation in the User's… 2013.}

Checking one field mapping is verification of that requirement. Validation of the changed process requires the combined evidence from the intended workflow. Existing analyzer installation and performance qualification does not establish that the new interface transmits results correctly. Testing only routine cases would have missed the false-negative result that made this change unsafe to introduce. Include invalid, blank, and interrupted cases in the challenge set, because a changed process is most likely to fail in those cases.^{88 US Food and Drug Administration. Blood Establishment Computer System Validation in the User's… 2013.}

Staff use policies for organizational rules, process descriptions for how activities connect, and procedures for the steps in a task. Package inserts, job aids, forms, decision tables, and downtime instructions also require control when staff use them to perform or interpret work. Document control records the owner, approval, version, effective date, revision history, and distribution. Remove superseded copies from points of use and handle them under the retention policy.

Blood bank records document work as it occurs, preserving the identity of the person performing each critical step, the date and time, observations, results and interpretations, reagent and supply lots when applicable, equipment, patient or donor, unit, and final disposition. Corrections must preserve the original entry and identify who changed it, when, and why.^{11 Association for the Advancement of Blood &… Standards for Blood Banks and Transfusion Services. 2026.}

CLIA requires at least 2 years of retention for test requisitions, analytic-system records, proficiency-testing records, quality-system assessment records, and reports, with specific longer rules for some records. A discontinued test procedure is retained for at least 2 years after its discontinuation.^{99 Electronic Code of Federal Regulations. 42 CFR §493.1105. 2026.}

Transfusion-related immunohematology and product records follow the incorporated FDA period: retain an individual product record for at least 10 years after processing records are completed or 6 months after the latest expiration date, whichever is later. A product record with no expiration date is retained indefinitely.^{44 Electronic Code of Federal Regulations. 21 CFR §606.160. 2026.}

The retention schedule must also account for longer state, accreditation, medical-record, legal, or institutional requirements that apply to the facility.

CLIA immunohematology proficiency-testing programs provide at least 5 samples per testing event and at least 3 events at approximately equal intervals each year. Each listed test has at least 5 challenges per event.^{1010 Electronic Code of Federal Regulations. 42 CFR §493.801. 2026.}

Routine testing personnel must process proficiency samples with the regular workload, routine method, and usual number of repetitions. The laboratory must document every testing and reporting step and retain the signed attestation for at least 2 years. Before the event deadline, personnel must not discuss results with another laboratory or testing site. The laboratory must not send a sample to another laboratory for analysis that it is certified to perform.^{1010 Electronic Code of Federal Regulations. 42 CFR §493.801. 2026.}

CAP recommends review of every unacceptable response, including a clerical error and an event with an acceptable overall score. The laboratory determines the cause and matches the response to the risk. An unsuccessful event requires review of the whole testing process and corrective action for each unacceptable result.^{1111 College of American Pathologists. Proficiency testing/external quality assessment frequently asked… 2026.}

External inspections provide another assessment. AABB and CAP assess the facility against their current requirements for the activities within its accreditation scope. Inspectors review current controlled documents and routine records as evidence of sustained compliance.

A nonconformance is a failure to meet a requirement. It may begin with a rejected specimen, failed control, temperature excursion, incorrect result, mislabeled unit, complaint, postdonation information, proficiency-testing miss, transfusion reaction, or audit finding. The investigation follows the affected process across departments.

1. Contain the risk. Stop the affected activity, hold results, quarantine units, preserve specimens and records, and use the approved alternate process when service must continue.
2. Define the scope. Identify the time interval, reagent lots, equipment, software version, operators, specimens, results, components, recipients, and customers that may be affected.
3. Correct the event. Resolve the immediate result, record, unit, or service problem and notify the responsible clinical or product parties.
4. Determine causes. Examine procedure design, training, workload, environment, reagent, equipment, interface, communication, and supervision evidence.
5. Implement corrective action. Remove or control the cause, revise and approve documents, revalidate the affected process, and retrain or reassess personnel as indicated.
6. Check effectiveness. Define follow-up evidence and a review date, confirm that the process stays within criteria, and trend related events for recurrence.

Resolving the immediate event is called a correction or remedial action. Corrective action addresses the cause and includes follow-up checks to establish whether it has controlled the risk of recurrence. CLIA and AABB both require documented review of corrective-action effectiveness.^{1,21 Association for the Advancement of Blood &… Standards for Blood Banks and Transfusion Services. 2026.2 Centers for Medicare & Medicaid Services. State Operations Manual, Appendix C. 2026.}

Internal investigation determines whether an event also meets an external reporting trigger. The applicable authority sets the reporting deadline, the facility responsible for reporting, and the destination of the report. The table summarizes the current federal and AABB triggers.^{3,7,123 US Food and Drug Administration. Biological product deviations. 2026.7 Association for the Advancement of Blood &… Significant Changes and Response to Comments Received to the… 2026.12 US Food and Drug Administration. Transfusion/donation fatalities.}

An internal assessment traces actual work through the full process. A unit tracer can follow one donation identification number from receipt through testing, storage, issue, transfusion, return, or discard. A patient tracer can follow the request, specimen, current and historical results, component selection, crossmatch, issue, and reaction record. The assessor compares each step with the procedure version, training and competency record, reagent and equipment record, interface or manual entry, and final disposition.

Quality indicators quantify recurring process performance. Blood bank indicators include:

• rejected or mislabeled specimens by cause and location;
• unresolved ABO discrepancies and corrected blood-group reports;
• emergency-release records completed within the facility's required interval;
• compatibility-testing turnaround time for a defined priority;
• temperature excursions and components lost after excursions;
• component outdates and wastage by cause;
• transfusion-reaction investigations completed within the required interval;
• proficiency-testing misses and recurrence after corrective action; and
• interface, label, or manual-entry discrepancies detected before issue.

For each indicator, the quality plan defines the numerator, denominator, included population, data source, owner, review interval, threshold, and response. Trend review distinguishes an isolated event from a recurring process problem. Management review uses internal assessments, external inspections, complaints, proficiency testing, and quality indicators to assign resources and follow corrective action until its effectiveness is measured.^{1,2,51 Association for the Advancement of Blood &… Standards for Blood Banks and Transfusion Services. 2026.2 Centers for Medicare & Medicaid Services. State Operations Manual, Appendix C. 2026.5 College of American Pathologists. Accreditation checklists. 2026.}